Should You Continue to Retain OMCL Stock in Your Portfolio Now?
CRL Stock May Benefit From New Neuroscience Research Collaboration
Express News | AxoGen Inc - FDA to Notify AxoGen on Bla Review Acceptance Within 60 Days
Express News | AxoGen Inc - FDA Determination of Approvability Expected Between April and September 2025
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft
Express News | AxoGen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?
AxoGen (NASDAQ:AXGN) Delivers Shareholders Splendid 105% Return Over 1 Year, Surging 13% in the Last Week Alone
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
Cytosorbents: Mariani Previously Served as CFO of Axogen >CTSO
Express News | Cytosorbents Corp - Kathleen P. Bloch Announced Her Retirement From Co
Express News | Cytosorbents Appoints Peter J. Mariani Chief Financial Officer
AxoGen Second Quarter 2024 Earnings: Beats Expectations
AxoGen Appoints New CEO and Board Chair for Strategic Renewal
Express News | JMP Securities Maintains Market Outperform on Axogen, Raises Price Target to $20
Axogen Analyst Ratings
Express News | AxoGen Inc : Raymond James Raises Target Price to $15 From $13
Buy Rating Affirmed for AxoGen: Strong Q2 Performance and Strategic Leadership Amidst Market Growth Potential
AxoGen | 10-Q: Q2 2024 Earnings Report